{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:57:24Z","timestamp":1794023844929,"version":"4.8.0"},"reference-count":33,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1084259"],"award-info":[{"award-number":["OPP1084259"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Vi-polysaccharide conjugate vaccines are efficacious against typhoid fever in children living in endemic settings, their recent deployment is a promising step in the control of typhoid fever. However, there is currently no accepted correlate of protection. IgG and IgA antibodies generated in response to Vi conjugate or Vi plain polysaccharide vaccination are important but there are no definitive protective titre thresholds. We adapted a luminescence-based serum bactericidal activity (SBA) for use with S. Typhi and assessed whether bactericidal antibodies induced by either Vi tetanus toxoid conjugate (Vi-TT) or Vi plain polysaccharide (Vi-PS) were associated with protection in a controlled human infection model of typhoid fever. Both Vi-PS and Vi-TT induced significant increase in SBA titre after 28 days (Vi-PS; p &lt; 0.0001, Vi-TT; p = 0.003), however higher SBA titre at the point of challenge did not correlate with protection from infection or reduced symptom severity. We cannot eliminate the role of SBA as part of a multifactorial immune response which protects against infection, however, our results do not support a strong role for SBA as a mechanism of Vi vaccine mediated protection in the CHIM setting.<\/jats:p>","DOI":"10.3390\/microorganisms9071394","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T11:45:40Z","timestamp":1624880740000},"page":"1394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5821-1001","authenticated-orcid":false,"given":"Elizabeth","family":"Jones","sequence":"first","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"Jin","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Stockdale","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dold","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-7764","authenticated-orcid":false,"given":"Jennifer","family":"Hill","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"ref_1","first-page":"346","article-title":"The global burden of typhoid fever. Bull World Health Organ","volume":"82","author":"John","year":"2004","journal-title":"Bull. World Health Organ."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7189\/jogh.01.010401","article-title":"Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010","volume":"2","author":"Buckle","year":"2012","journal-title":"J. Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: A systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"Stanaway","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/cix229","article-title":"An Appraisal of the Clinical Features of Pediatric Enteric Fever: Systematic Review and Meta-analysis of the Age-Stratified Disease Occurrence","volume":"64","author":"Britto","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.1093\/cid\/ciz611","article-title":"The Invisible Burden: Diagnosing and Combatting Typhoid Fever in Asia and Africa","volume":"69","author":"Pitzer","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Jin, C., Gibani, M.M., Pennington, S.H., Liu, X., Ardrey, A., Aljayyoussi, G., Moore, M., Angus, B., Angus, C.M., and Biagini, G.A. (2019). Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007955"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QCO.0b013e328356ffeb","article-title":"Vaccines for typhoid fever and other salmonelloses","volume":"25","author":"Martin","year":"2012","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.4161\/hv.29054","article-title":"Vaccines against invasive Salmonella disease: Current status and future directions","volume":"10","author":"MacLennan","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the Typhoid Conjugate Vaccine Pipeline: Current Status and Future Plans","volume":"68","author":"Sahastrabuddhe","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: A randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and Immunogenicity of a Vi Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: Correlates of Vaccine-Induced Immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3389\/fimmu.2019.02582","article-title":"IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model","volume":"10","author":"Dahora","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jin, C., Hill, J., Gunn, B.M., Yu, W.-H., Dahora, L.C., Jones, E., Johnson, M., Gibani, M.M., Spreng, R.L., and Alamet, S.M. (2020). Vi-specific serological correlates of protection for typhoid fever. J. Exp. Med., 218.","DOI":"10.1084\/jem.20201116"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/00325481.2019.1696582","article-title":"Understanding immunogenicity assessments for meningococcal serogroup B vaccines","volume":"132","author":"Balmer","year":"2020","journal-title":"Postgrad. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/CVI.00245-09","article-title":"Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal","volume":"16","author":"Pulickal","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01916","article-title":"Salmonella Typhi bactericidal antibodies reduce disease severity but do not protect against typhoid fever in a controlled human infection model","volume":"8","author":"Juel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/cid\/ciu078","article-title":"An outpatient, ambulant-design, controlled human infection model using escalating doses of salmonella typhi challenge delivered in sodium bicarbonate solution","volume":"58","author":"Waddington","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jim.2018.06.025","article-title":"Setup of luminescence-based serum bactericidal assay against Salmonella Paratyphi A","volume":"461","author":"Necchi","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/1040841X.2016.1249335","article-title":"Vi capsular polysaccharide: Synthesis, virulence, and application","volume":"43","author":"Hu","year":"2017","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1128\/CVI.00115-14","article-title":"Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines","volume":"21","author":"Boyd","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1128\/IAI.05081-11","article-title":"Antibodies in action: Role of human opsonins in killing Salmonella enterica serovar Typhi","volume":"79","author":"Lindow","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1099\/jmm.0.047159-0","article-title":"Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay","volume":"62","author":"Ahmadi","year":"2013","journal-title":"J. Med. Microbiol."},{"key":"ref_25","first-page":"1","article-title":"IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity","volume":"14","author":"Yang","year":"2019","journal-title":"PLoS ONE"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CVI.00412-16","article-title":"Functional and antigen-specific serum antibody levels as correlates of protection against shigellosis in a controlled human challenge study","volume":"24","author":"Shimanovich","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.micres.2011.08.001","article-title":"Role of antigens and virulence factors of Salmonella enterica serovar Typhi in its pathogenesis","volume":"167","author":"Kaur","year":"2012","journal-title":"Microbiol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hart, P.J., O\u2019Shaughnessy, C.M., Siggins, M.K., Bobat, S., Kingsley, R.A., Goulding, D.A., Crump, J.A., Reyburn, H., Micoli, F., and Dougan, G. (2016). Differential killing of Salmonella enterica serovar Typhi by antibodies targeting VI and lipopolysaccharide O:9 antigen. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0145945"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.celrep.2018.01.016","article-title":"Mechanisms to Evade the Phagocyte Respiratory Burst Arose by Convergent Evolution in Typhoidal Salmonella Serovars","volume":"22","author":"Hiyoshi","year":"2018","journal-title":"Cell Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Murphy, K., Travers, P., and Walport, M. (2008). Janeway\u2019s Immunobiology, Garland Science. [7th ed.].","DOI":"10.1007\/978-3-8274-2219-4"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.1991.tb08115.x","article-title":"The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: A systematic study using chimaeric anti-NIP antibodies with human Fc regions","volume":"84","author":"Valim","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/imcb.12306","article-title":"Serum IgA Fc effector functions in infectious disease and cancer","volume":"98","author":"Davis","year":"2020","journal-title":"Immunol. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","article-title":"Updates on immunologic correlates of vaccine-induced protection","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/7\/1394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:25:50Z","timestamp":1760163950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/7\/1394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["microorganisms9071394"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms9071394","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]}}}